Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

• Market Cap: ₹18.43B
• Dividend Yield: 0.29%
• Average Volume (3M): 114.38K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 1.47
• Revenue Growth: 4.93%
• EPS Growth: 29.92%
• Country: IN
• Employees: 831
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.08
• Shares Outstanding: 105,497,520
• 10 Day Avg. Volume: 285,272
• 30 Day Avg. Volume: 114,381
• PEG Ratio: 1.37
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.56
• P/FCF Ratio: 42.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹200.00
• Price Target Upside: 14.51% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹200.00 ▲(14.51% Upside)

Bliss Gvs Pharma Limited's overall stock score reflects its strong financial performance driven by a solid balance sheet and revenue growth. The technical analysis indicates bullish momentum, though the overbought RSI suggests caution. Valuation metrics show the stock is fairly valued, but with a low dividend yield. The absence of earnings call insights and corporate events did not impact the scoring.

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Bliss GVS Pharma Limited (BLISSGVS) is an Indian pharmaceutical company that specializes in the manufacturing and distribution of a wide range of pharmaceutical formulations. The company operates in the healthcare sector, focusing primarily on generic medicines and over-the-counter products. Bliss GVS Pharma is known for its innovative drug delivery systems and has a significant presence in both domestic and international markets.

How the Company Makes Money

Bliss GVS Pharma Limited generates revenue through the production and sale of pharmaceutical formulations. The company's key revenue streams include the sale of generic medicines and over-the-counter healthcare products. Bliss GVS Pharma also engages in contract manufacturing and exports its products to various international markets, which significantly contributes to its earnings. The company maintains strategic partnerships and collaborations to enhance its product offerings and expand its market reach, further supporting its revenue generation.

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Bliss Gvs Pharma Limited exhibits a robust financial performance with a strong balance sheet and improving income statement metrics. The company demonstrates healthy revenue growth and profitability, although cash flow management could be further optimized to enhance liquidity. The low leverage and strong equity position provide a solid foundation for future growth.

Income Statement

Bliss Gvs Pharma Limited has shown consistent revenue growth over the years, with a notable increase in gross and net profit margins in the latest year. The EBIT and EBITDA margins have improved, indicating efficient cost management and operational performance. While the revenue growth trajectory is positive, there could be improved consistency in EBITDA performance.

Balance Sheet

The company maintains a strong balance sheet with a high equity ratio and low debt-to-equity ratio, showcasing financial stability and low leverage. The return on equity has seen improvement, reflecting the company's ability to generate profits from shareholders' equity. The company's strong equity position is a key strength.

Cash Flow

The cash flow position has been mixed, with variability in free cash flow growth rates. The operating cash flow to net income ratio indicates a healthy cash conversion cycle, but the free cash flow to net income ratio suggests room for improvement. The company should focus on optimizing capital expenditures to enhance free cash flow.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.10B	8.10B	7.66B	7.38B	7.52B	5.69B
Gross Profit	3.28B	3.96B	2.49B	3.47B	3.50B	2.40B
EBITDA	1.63B	1.27B	1.49B	762.37M	1.35B	1.27B
Net Income	842.99M	842.99M	754.54M	150.40M	708.59M	684.91M
Balance Sheet
Total Assets	13.01B	13.01B	12.14B	11.09B	11.57B	10.77B
Cash, Cash Equivalents and Short-Term Investments	2.13B	2.13B	1.41B	1.46B	1.12B	621.66M
Total Debt	881.04M	881.04M	998.40M	1.09B	1.02B	1.22B
Total Liabilities	2.09B	2.09B	2.11B	2.62B	2.39B	2.49B
Stockholders Equity	10.50B	10.50B	9.67B	8.19B	8.84B	8.08B
Cash Flow
Free Cash Flow	0.00	298.48M	1.24B	614.77M	-594.86M	548.45M
Operating Cash Flow	0.00	1.06B	1.52B	1.35B	343.13M	639.69M
Investing Cash Flow	0.00	-754.41M	-1.33B	-929.75M	-77.51M	-469.91M
Financing Cash Flow	0.00	-303.45M	-208.93M	-237.30M	-249.38M	-207.98M

Bliss Gvs Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 174.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 174.65 is above the 20-day moving average (MA) of 167.53, above the 50-day MA of 156.50, and above the 200-day MA of 141.74, indicating a bullish trend. The MACD of 5.98 indicates Positive momentum. The RSI at 55.12 is Neutral, neither overbought nor oversold. The STOCH value of 17.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAGSNPHARM	74 Outperform	₹16.48B	27.07		0.79%	34.72%	196.57%
WINDLAS	70 Outperform	₹20.10B	30.71		0.63%	20.43%	4.36%
HESTERBIO	68 Neutral	₹16.48B	43.83		0.36%	4.68%	94.22%
BLISSGVS	67 Neutral	₹18.43B	17.25		0.29%	4.93%	29.92%
SYNCOMF	62 Neutral	₹16.64B	30.30		―	70.43%	92.33%
BAJAJHCARE	52 Neutral	₹14.64B	32.28		0.22%	17.50%	―
Sector *	51 Neutral	kr6.00B	8.78	-28.70%	2.24%	51.61%	19.20%

Bliss Gvs Pharma Limited Corporate Events

Bliss GVS Pharma Expands Share Capital with New ESOP Allotment

Bliss GVS Pharma Limited announced the allotment of 52,000 equity shares under its Employee Stock Option Plan 2019, increasing its total issued share capital. This move reflects the company’s commitment to rewarding its employees and may enhance employee retention and motivation, potentially impacting its operational efficiency and market positioning positively.